Small molecule · Inhibitor of muscle glycogen synthase · developed by Maze Therapeutics
MZE001 is a small molecule inhibitor of muscle glycogen synthase, the enzyme that drives glycogen synthesis in skeletal muscle. It is studied in healthy participants.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05249621 | Phase 1 | Healthy | Completed | MAZE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Healthy
Updated Oct 18, 2026. Something wrong or missing? Report it on the MAZE page.
See MAZE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MAZE catalysts and pipeline →